A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Vibegron (Primary)
- Indications Neurogenic bladder; Overactive bladder
- Focus Therapeutic Use
- Acronyms KANGUROO
- Sponsors Sumitomo Pharma America; Urovant Sciences
- 12 Jun 2023 Planned primary completion date changed from 1 Mar 2027 to 1 Jan 2027.
- 12 Jun 2023 Status changed from not yet recruiting to recruiting.
- 12 Aug 2022 New trial record